在铁缺乏症患者的铁碳素中,患者患有住院心力衰竭和功能减弱
Iain C Macdougall1, Piotr Ponikowski2, Austin G Stack3
1Department of Renal Medicine, King's College Hospital, London, United Kingdom.
概括
在急性心力衰竭和铁缺乏症患者中,静脉注射铁糖可减少心力衰竭住院,无论功能如何. 这种治疗改善了功能受损患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 降低功能在心力衰竭患者中很普遍.
- 缺铁独立地预测了心力衰竭和脏疾病的不良结果.
- 在AFFIRM-AHF试验中,对铁缺乏症急性心力衰竭患者的静脉输入铁性碳糖糖糖呈现出前景.
研究的目的:
- 评估铁性碳糖在急性心力衰竭患者同时存在功能障碍的疗效和安全性.
- 分析铁性碳酸在不同估计的膜过率 (eGFR) 水平上的影响.
主要方法:
- 在AFFIRM-AHF试验中,有1132名患有急性心力衰竭 (LVEF <50%) 和铁缺乏症的患者随机选择了铁性碳素糖或安慰剂.
- 根据基线eGFR对患者进行了分层,以分析具有降低 (<60毫升/分钟/1.73米2) 和保留功能的子组.
- 主要终点:52周内心力衰竭住院和心血管死亡的综合结果.
主要成果:
- 60%的患者降低了EGFR (<60毫升/分钟/1.73米2),出现了较高的贫血和并发病率.
- 铁性碳素马尔托在降低所有eGFR子组的初级复合结果方面表现出一致的治疗效果.
- 对于初级结局,年化事件率为每100个患者年中的68.96个,在较低的EGFR组中,铁性碳素马尔托与安慰剂的86.30个相比 (RR 0.76).
结论:
- 铁性碳酸对于患有急性心力衰竭,缺铁和不同程度的功能障碍的患者来说是安全有效的.
- 铁性碳酸治疗的好处在功能减弱和维持的患者中是一致的.
- 这支持在患有铁缺乏症的急性心力衰竭患者中更广泛地使用铁性碳糖.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:11Renal Failure: Dose Adjustments
127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
01:22Heart Failure Drugs: Diuretics
425
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
425
01:26Heart Failure Drugs: Inotropic Agents
640
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467